Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 5/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15628455 | 0.95 | LOXL2 (0.36) | HRH3MAOBLOXL2CYP1A2CYP2D6 | |
| SCHEMBL20026348 | 0.86 | ERN1 (0.33) | CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL19063250 | 0.82 | TSHR (0.39) | TAAR1CYP1A2CYP2D6CYP2C19SLC6A4 | |
| SCHEMBL20026377 | 0.81 | CYP1A2 (0.34) | CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL15628463 | 0.81 | CYP1A2 (0.34) | CYP1A2CYP2D6CYP2C19LTA4H | |
| SCHEMBL19062812 | 0.81 | CYP1A2 (0.34) | CYP1A2CYP2D6CYP2C19LTA4H | |
| SCHEMBL19062561 | 0.80 | ATM (0.35) | CYP2A6 | |
| SCHEMBL17490437 | 0.80 | ATM (0.35) | CYP2A6 | |
| SCHEMBL19062433 | 0.78 | ALDH1A1 (0.34) | MAOBCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL20026227 | 0.78 | TDP1 (0.34) | CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | IL33, PROKR1, VIP | HRH3 406/4885TAAR1 2916/4885BACE1 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.